Litcius/Paper detail

Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial

Takashi Kadowaki, Arihiro Kiyosue, Tomotaka Shingaki, Tomonori Oura, Koutaro Yokote

2025The Lancet Diabetes & Endocrinology34 citationsDOI

Topics & Concepts

MedicinePlaceboPhysical therapyObesityClinical trialDouble blindDiseaseAlternative medicineIntensive care medicineInternal medicinePathologyDiabetes, Cardiovascular Risks, and LipoproteinsPharmacology and Obesity TreatmentCardiovascular Disease and Adiposity
Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial | Litcius